Sugi Predict

Sugi Predict / Compounds / Desmethoxyyangonin

Desmethoxyyangonin

Desmethoxyyangonin

SCHEMBL236641

COc1cc(C=Cc2ccccc2)oc(=O)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 1.00
▸ HPGD P15428 5/20 1.00
▸ SMN1; SMN2 Q16637 4/20 1.00
▸ TP53 P04637 3/20 1.00
▸ CYP3A4 P08684 2/20 1.00
▸ MAPT P10636 5/20 0.82
▸ HSD17B10 Q99714 2/20 0.82
▸ CASP1 P29466 1/20 0.82
▸ CASP7 P55210 1/20 0.82
▸ HIF1A Q16665 1/20 0.64
▸ TRPA1 O75762 1/20 0.56
▸ KDM4E B2RXH2 4/20 0.52
▸ MEN1 O00255 1/20 0.51
▸ USP2 O75604 1/20 0.51
▸ KMT2A Q03164 1/20 0.51
▸ TRPV1 Q8NER1 1/20 0.51
▸ MAOA P21397 2/20 0.48
▸ MAOB P27338 2/20 0.48
▸ NPC1 O15118 2/20 0.48
▸ RAB9A P51151 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Desmethoxyyangonin SCHEMBL3630674 1.00 ALDH1A1 (1.00) ALDH1A1HPGDSMN1; SMN2TP53CYP3A4
Yangonin SCHEMBL1393965 0.90 ALDH1A1 (1.00) ALDH1A1HPGDSMN1; SMN2TP53CYP3A4
Yangonin SCHEMBL5584097 0.90 ALDH1A1 (1.00) ALDH1A1HPGDSMN1; SMN2TP53CYP3A4
SCHEMBL9016266 0.86 MAPT (0.80) ALDH1A1HPGDSMN1; SMN2TP53CYP3A4
SCHEMBL9016268 0.86 MAPT (0.80) ALDH1A1HPGDSMN1; SMN2TP53CYP3A4
SCHEMBL9016241 0.82 HIF1A (0.78) ALDH1A1HPGDSMN1; SMN2TP53CYP3A4
SCHEMBL29584432 0.82 HIF1A (0.78) ALDH1A1HPGDSMN1; SMN2TP53CYP3A4
SCHEMBL9016238 0.82 HIF1A (0.78) ALDH1A1HPGDSMN1; SMN2TP53CYP3A4
SCHEMBL19665470 0.81 HIF1A (0.80) ALDH1A1HPGDSMN1; SMN2TP53CYP3A4
SCHEMBL19665468 0.81 HIF1A (0.80) ALDH1A1HPGDSMN1; SMN2TP53CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 557 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12582153-B2 Oral formulations of kava and nicotine ROSS JERRY WAYNE (US) 2026-03-24 — — US claimed
WO-2025245170-A1 ORAL FORMULATIONS OF KAVA ROSS JERRY WAYNE (US) 2025-11-27 — — WO claimed
US-20250351862-A1 Oral Formulations of Kava and Nicotine ROSS JERRY WAYNE (US) 2025-11-20 — — US claimed
US-20250351863-A1 Oral Formulations of Kava ROSS JERRY WAYNE (US) 2025-11-20 — — US claimed
US-12419927-B2 Kava compositions and methods of use BOTANIC TONICS LLC (US) 2025-09-23 — — US claimed
US-20250213637-A1 KAVA DERIVED THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF KUALITY HERBCEUTICS LLC (US) 2025-07-03 — — US claimed
US-12310395-B1 Oral formulations of kava and nicotine ROSS JERRY WAYNE (US) 2025-05-27 — — US claimed
US-20250161394-A1 Compositions Comprising Kavalactones NATURAL EXTRACTION SYS LLC (US) 2025-05-22 — — US claimed
US-20240261358-A1 KAVA COMPOSITIONS AND METHODS OF USE BOTANIC TONICS LLC (US) 2024-08-08 — — US claimed
EP-4401713-A1 ALIMENTARY-RELATED PARTICLES, PRODUCTION METHODS, AND PRODUCTION APPARATUS Nulixir Inc. (US) 2024-07-24 — — EP claimed
WO-2003031597-A2 METHODS OF INHIBITING OSTEOCLAST ACTIVITY KAVA PHARMACEUTICALS, INC. (US) 2003-04-17 — — WO claimed
WO-2003028662-A2 A METHOD OF PRODUCING A PROCESSED KAVA PRODUCT HAVING AN ALTERED KAVALACTONE DISTRIBUTION AND PROCESSED KAVA PRODUCTS PRODUCED USING THE SAME HERBALSCIENCE, LLC (US) 2003-04-10 — — WO claimed
WO-2003013436-A2 KAVALACTONE COMPOSITIONS AND METHODS OF USE KAVA PHARMACEUTICALS, INC. (US) 2003-02-20 — — WO claimed
US-20030013639-A1 Sleep inducing antacid composition YURCHAK LISA (US) 2003-01-16 — — US claimed
US-20030012824-A1 Orally administered anti-stress composition OTT DANA BETH (US) 2003-01-16 — — US claimed
US-20020192241-A1 Methods of using kavalactone compositions SYNTA PHARMACEUTICALS CORP. 2002-12-19 — — US claimed
WO-2002091966-A1 KAVALACTONE COMPOSITIONS AND METHODS OF USE KAVA PHARMACEUTICALS, INC. (US) 2002-11-21 — — WO claimed
US-20020173540-A1 TNF-alpha production inhibitor comprising kavalactone as an active ingredient MEIJI DAIRIES CORPORATION (JP) 2002-11-21 — — US claimed
EP-1222925-A2 Kavalactone as TNF-alpha production inhibitor Meiji Dairies Corporation (JP) 2002-07-17 — — EP claimed
US-20020077351-A1 TNF-alpha production inhibitor comprising kavalactone as an active ingredient MEIJI DAIRIES CORPORATION (JP) 2002-06-20 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12582153-B2 Oral formulations of kava and nicotine PDK2, PDHA1, LDHA ALDH1A1 1359/4885HPGD 64/4885SMN1; SMN2 4081/4885
US-20250213637-A1 KAVA DERIVED THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF KLK5, KLK4, KLK2 ALDH1A1 1649/4885HPGD 495/4885SMN1; SMN2 2154/4885
US-20020077351-A1 TNF-alpha production inhibitor comprising kavalactone as an active ingredient TNF, TNFRSF1A, TNFRSF9 ALDH1A1 2222/4885HPGD 1485/4885SMN1; SMN2 2127/4885
US-20020173540-A1 TNF-alpha production inhibitor comprising kavalactone as an active ingredient TNF, TNFRSF1A, TNFRSF9 ALDH1A1 2222/4885HPGD 1485/4885SMN1; SMN2 2127/4885
US-20020192241-A1 Methods of using kavalactone compositions KHK, KLK4, KLK14 ALDH1A1 2705/4885HPGD 378/4885SMN1; SMN2 2089/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.